Atherosclerosis Monitoring and Atherogenicity Reduction Study

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study was designed to estimate the effect of two-year treatment with time-released garlic-based drug Allicor on the progression of carotid atherosclerosis in double-blinded placebo-controlled randomized clinical trial.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Institute for Atherosclerosis Research, Russia

Criteria

Inclusion Criteria:

• Men aged 40 to 74 years

• Subclinical carotid atherosclerosis detected by B-mode ultrasound (increased intima-media thickness 1100-2000 mcm)

• Arterial normotension or mild arterial hypertension (systolic blood pressure <160 mm Hg, diastolic blood pressure <90 mm Hg)

• Absence of chronic diseases demanding permanent drug administration (more than 2 month per year)

Exclusion Criteria:

• Personal history or diagnostic of following diseases:

1. Transient ischemic attacks

2. Presence of chronic diseases demanding permanent drug administration (more than 2 month per year)

3. Condition of patients moderate to severe

• Indications for surgical treatment of atherosclerotic lesions localized in the extracranial brachiocephalic system.

• Individual intolerance of Allicor or appearance of side effects